In addition, hypomagnesemia, mild elevation of alanine aminotransferase, and gastrointestinal disturbances were more frequent in the bardoxolone methyl group than those in the placebo group, suggesting that bardoxolone methyl may be a promising treatment for DKD. This evidence concerns the gene GPT and Hypomagnesemia.